In gastric cancer, aberrant METTL3 has long been recognized as a marker of poor patient prognosis, and enhanced METTL3 up-modulated m6A modification of ZMYM1 mRNA [17], DEK mRNA [18] or HDGF mRNA [19] to induce tumor growth and distant metastasis. This evidence concerns the gene METTL3 and neoplasm.